Treatment patterns, health care resource utilization and costs of rheumatoid arthritis patients in Italy: findings from a retrospective administrative database analysis
Walid Fakhouri,1 Pedro Lopez-Romero,2 Silvia Antonelli,3 Serena Losi,4 Veronica Rogai,4 Stefano Buda,5 Diego Sangiorgi,5 Valentina Perrone,5 Luca Degli Esposti5 1Eli Lilly & Company, Erl Wood, UK; 2Eli Lilly & Company, Madrid, Spain; 3Eli Lilly Italy S.p.A., Roma, I...
Enregistré dans:
Auteurs principaux: | Fakhouri W, Lopez-Romero P, Antonelli S, Losi S, Rogai V, Buda S, Sangiorgi D, Perrone V, Degli Esposti L |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2018
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/06221df7cf294e5fadc47b4b581f0ab7 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Tofacitinib: Real-World Data and Treatment Persistence in Rheumatoid Arthritis
par: Bertoldi I, et autres
Publié: (2021) -
The onset of rheumatoid arthritis following trauma
par: Brawer AE, et autres
Publié: (2016) -
Current and Emerging DMARDs for the Treatment of Rheumatoid Arthritis
par: Mysler E, et autres
Publié: (2021) -
Clinical and serological characteristics of Ecuadorian patients with rheumatoid arthritis
par: Ríos C, et autres
Publié: (2017) -
Risk Factors Associated with Methotrexate Intolerance in Rheumatoid Arthritis Patients
par: Almalag H, et autres
Publié: (2020)